Tuesday 22 January 2013

Celgene's Abraxane increases survival in pancreatic cancer

(Reuters) - Celgene Corp said its Abraxane drug helped patients with advanced pancreatic cancer live an average of two months longer than chemotherapy and significantly increased the percentage of those who survived with the disease for up to two years, according to a late-stage study. Based on the results, Celgene said it expects to file applications in the United States and Europe in the first half of this year seeking approval for the use of Abraxane for pancreatic cancer. ... via Health News Headlines - Yahoo! News Read More Here..

No comments:

Post a Comment